Summary
Epidemiology: Eleven prospective epidemiological studies from various countries have as yet evaluated the gene prevalence of HLA-linked hemochromatosis. The estimated frequency ranged from 0.027-0.107, the frequency of homozygotes from 0.00074-0.0116, and the frequency of heterozygotes from 0.052-0.191. In a meta-analysis of the eleven surveys the frequency is 0.0016 (106/64758 subjects) for homozygotes which corresponds to a gene frequency of 0.041 and a frequency of heterozygotes of 0.078. Further analyses showed that some of these studies have probably underestimated the prevalence which in reality is probably two- to threefold higher than estimated by the meta-analysis.
Clinical spectrum: In the total group of 251 patients diagnosed with hemochromatosis in the University of Diisseldorf from 1959–1992, abnormality in liver function tests (75%), weakness and lethargy (74%), skin hyperpigmentation (70%), diabetes mellitus (48%), arthralgia (44%), impotence (45% in males), and ECG abnormalities (31%) were the most frequent findings and symptoms at diagnosis. In recent years about 50% of patients were detected without having liver cirrhosis and 20% of patients did not have any symptoms and pathology except iron overload.
Prognosis: Survival analysis in the 251 patients showed that in the absence of cirrhosis and diabetes iron removal by phlebotomy therapy prevents further tissue damage and guarantees a normal life expectancy. Sex and presence of arthropathy did not predict prognosis. However, patients with massive and long-lasting iron overload had a worse prognosis than patients with less severe iron excess. Iron removal in general ameliorated liver disease, weakness and cardiac abnormalities, and also prevented the progression of endocrine alterations. Therapy, however, did not influence arthropathy which even got worse in several patients. Iron removal also failed to reverse insulin-dependent diabetes. During a mean followup of 13.4 years 69 deaths occurred in the 251 patients. In 19 patients death was due to liver cancer, in 14 due to liver cirrhosis, in 5 due to cardiomyopathy, and in 3 due to diabetes mellitus (all causes significantly more frequent than expected for the general population). The other causes of death were as frequent as expected including extrahepatic malignancies. All liver cancers were seen in cirrhotic livers, but often occurred many years or even decades after complete iron removal. Further strategies have to evaluate the design of screening programs in order to diagnose more patients in the precirrhotic and asymptomatic stage.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Adams, P.C., Speechley, M., Kertesz, A.E., 1991, Long-term survival analysis in hereditary hemochromatosis, Gastroenterology 101: 368.
Ammann, R.W., Müller, E., Bansky, J., Schüler, G., Häcki, W.H., 1980, High incidence of extrahepatic carcinoma in idiopathic haemochromatosis, Scan J Gastroenterol 15: 733.
Bain, C., Bradbear, R., Siskind, U., Schofield, F., Bassett, M., Halliday J., Powell, L., 1984, Cohort study of the risk of malignancy in hemochromatosis and other nonalcoholic liver diseases, Hepatology 4:A1020.
Balfour, W.M., Hahn, P.F., Bale, W.F., Pommerenke, W.T., Whipple, G.H., 1942, Radioactive iron absorption in clinical conditions: normal, pregnancy, anemia, and hemochromatosis, J Exp Med 76: 15.
Bomford, A., Williams, R., 1976, Long term results of venesection therapy in idiopathic hemochromatosis, Q J Med 45: 611.
Borwein, S.T., Ghent, C.N., Flanagan, P.R., Chamberlain, M.J., Valberg, L.S., 1983, Genetic and phenotypic expression of hemochromatosis in Canadians, Gin Inv Med 6: 171.
Cartwright, G.E., Edwards, C.Q., Kravitz, K., Skolnick, M., Amos, D.B., Johnson, A., Buskjaer, L., 1979, Hereditary hemochromatosis: phenotypic expression of the disease, N Engl J Med 301: 175.
Cox, T.M., Peters, F.J., 1978, Uptake of iron by duodenal biopsy specimens from patients with iron-deficiency anaemia and primary hemochromatosis, Lancet 1: 123.
Dadone, M.M., Kushner, J.P., Edwards, C.Q., Bishpo, D.T., Skolnick, M.H., 1982, Hereditary hemochromatosis: analysis of laboratory expression of the disease by genotype in 18 pedigrees, Am J Cin Pathol 78: 196.
Edwards, C.Q., Griffen, L.M., Goldgar, D., Drummond, C., Skolnick, M.H., Kushner, J.P., 1988, Prevalence of hemochromatosis among 11,065 presumably healthy blood donors, N Engl J Med 318: 1355.
Elliott, R., Tait, A., Lin, B.P.C., Smith, C.I., Dent, O.F., 1986, Prevalence of hemochromatosis in a random sample of asymptomatic men, Aust NZ J Med 16: 491.
Expert Scientific Working Group, 1985, Summary of a report on assessment of the iron nutritional status of the United States, Am J Clin Nutr 42: 318.
Finch, C.A., 1949, Iron metabolism in hemochromatosis, J Cin Invest 28: 780.
Finch, S.C., Finch, C.A., 1966, Idiopathic hemochromatosis, an iron storage disease, Medicine 34: 381.
Hallberg, L., Björn-Rasmussen, E., Jungner, I., 1989, Prevalence of hereditary hemochromatosis in two Swedish urban areas, J Int Med 225: 249.
Hines, C., Davis W.D., Ferrante, W.A., 1971, Hepatoma developing in hemochromatosis in spite of treatment by multiple phlebotomies, Am J Dig Dis 16: 349.
Hurst, P.E., Kakulas, B.A., Walters, M.N.I., 1961, Hepatoma developing in treated hemochromatosis: report of a case, Med J Aust 48: 18.
Karlsson, M., Ikkala, E., Reunanen, A., Takkunen, H., Vuori, E., Mäkinen, J., 1988, Prevalence of hemochromatosis in Finland, Acta Med Scand 224: 385.
Lindmark, B., Eriksson, S., 1985, Regional differences in the idiopathic hemochromatosis gene frequency in Sweden, Acta Med Scand 218: 299.
MacDonald, R.A., 1965, Hemochromatosis and cirrhosis in different geographic areas, Am J Med Sci 1: 62/36.
MacDonald, R.A., Mallory, G.K., 1960, Hemochromatosis and hemosiderosis. Study in 211 autopsied cases, Arch Intern Med 105: 686.
MacSween, R.N.M., Scott, A.R., 1973, Hepatic cirrhosis: a clinicopathological review of 520 cases, J Clin Path 26: 936.
Meyer, T.E., Ballot, D., Bothwell, T.H., Green, A., Derman, D.P., Baynes, R.D., Jenkins, T., Jooste, P.L., DuTroit, E.D., Jacobs, P., 1987, The HLA linked iron loading gene in an Africaner population, J Med Gen 24: 348.
Meyer, T., Baynes, R., Bothwell, T., Jenkins, T., Jooste, P., DuToit, E., Martell, R., Jacobs, P., 1990, Phenotypic expression of the HLA linked iron-loading gene in males over the age of 40 years: a population study using serial serum ferritin estimation, J Int Med 227: 397.
Milder, M.S., Cook, J.D., Stray S., Finch, J.A., 1980, Idiopathic hemochromatosis, an interim report, Medicine 59: 34.
Niederau, C., Berger, M., Stremmel, W., Starke, A., Strohmeyer, G., Ebert, R., Siegel, E., Creutzfeldt, W., 1984, Hyperinsulinaemia in non-cirrhotic haemochromatosis: impaired hepatic insulin degradation?, Diabetologia 26: 441.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer Science+Business Media New York
About this chapter
Cite this chapter
Niederau, C., Strohmeyer, G., Stremmel, W. (1994). Epidemiology, Clinical Spectrum and Prognosis of Hemochromatosis. In: Hershko, C., Konijn, A.M., Aisen, P. (eds) Progress in Iron Research. Advances in Experimental Medicine and Biology, vol 356. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2554-7_31
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2554-7_31
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6090-2
Online ISBN: 978-1-4615-2554-7
eBook Packages: Springer Book Archive